Millipore Sigma Vibrant Logo

204885 Complement C3, Human

Complement C3, Human, CAS 80295-41-6, is a native C3 component. Glycoprotein composed of two non-identical disulfide-bonded subunits of 115 kDa (α) and 75 kDa (β).

Complement C3, Human: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。
View This Product on Sigma-Aldrich
204885
価格＆在庫状況を照会

概要

Replacement Information

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
204885-250UGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 250 μg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewNative, human C3 complement component. Glycoprotein composed of two non-identical disulfide-bonded subunits with M.W. of 115 kDa (α) and 75 kDa (β). Present in normal human serum at 1.25 mg/ml. Classical and alternative activation pathways of complement converge at C3 step. Activation via either pathway can result in assembly of C3-cleaving enzymes (C3 convertases) on target surfaces. Both C3 convertases cleave the C3 α-chain at peptide bond 77 resulting in production of C3a (M.W. 9083) and C3b fragments (M.W. 180,000). Released C3a peptide is one of the three complement anaphylatoxins. The nascent C3b fragment can form a covalent ester bond with target surface. This covalent attachment of C3b to target acceptors is required for continuation of complement activation.
      Catalogue Number204885
      Brand Family Calbiochem®
      References
      ReferencesLambris, J.D. and Muller-Eberhard, H.J. 1986. Mol. Immunol. 23, 1237.
      Tack, B.F., et al. 1980. Methods Enzymol. 80, 64.
      Product Information
      CAS number80295-41-6
      FormLiquid
      FormulationIn PBS.
      Quality LevelMQ100
      Applications
      Biological Information
      Biological activity>3,000 C₃H₅0 units/mg; ≥60% of the C3 activity in normal human serum on a mg/mg basis.
      Purity≥85% by SDS-PAGE
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Physicochemical Information
      ContaminantsIgG, IgA, IgM, C4, functionally active C5, albumin or ceruloplasmin: ≤trace amounts
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      204885-250UGCN 04055977219791

      Documentation

      Complement C3, Human (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      Complement C3, Human 試験成績書（CoA）

      タイトルロット番号
      204885

      参考資料

      参考資料の概要
      Lambris, J.D. and Muller-Eberhard, H.J. 1986. Mol. Immunol. 23, 1237.
      Tack, B.F., et al. 1980. Methods Enzymol. 80, 64.

      引用

      Title
    • Inal, J.M. and Schifferli J.A., 2002. Journal of Immunology 168, 5213.
      		•
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision29-June-2018 JSW
      DescriptionNative, human C3 complement component. Glycoprotein composed of two non-identical disulfide-bonded subunits with M.W. of 115,000 (α) and 75,000 (β). Present in normal human serum at 1.25 mg/ml. Classical and alternative activation pathways of complement converge at the C3 step. Activation via either pathway can result in assembly of C3-cleaving enzymes (C3 convertases) on target surfaces. Both C3 convertases cleave the C3 α-chain at peptide bond 77, resulting in production of C3a (M.W. 9083) and C3b fragments (M.W. 180,000). Released C3a peptide is one of the three complement anaphylatoxins. The nascent C3b fragment can form a covalent ester bond with target surface. The covalent attachment of C3b to target acceptors is required for continuation of complement activation.
      FormLiquid
      FormulationIn PBS.
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      CAS number80295-41-6
      Purity≥85% by SDS-PAGE
      ContaminantsIgG, IgA, IgM, C4, functionally active C5, albumin or ceruloplasmin: ≤trace amounts
      Biological activity>3,000 C₃H₅0 units/mg; ≥60% of the C3 activity in normal human serum on a mg/mg basis.
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesLambris, J.D. and Muller-Eberhard, H.J. 1986. Mol. Immunol. 23, 1237.
      Tack, B.F., et al. 1980. Methods Enzymol. 80, 64.
      Citation
    • Inal, J.M. and Schifferli J.A., 2002. Journal of Immunology 168, 5213.
      		•